Patent application number | Description | Published |
20090099942 | Identification of Discrepancies in Actual and Expected Inventories in Computing Environment having Multiple Provisioning Orchestration Server Pool Boundaries - A system for establishing and maintaining inventories of computing environment assets comprising one or more custom collector interfaces that detect movement of assets from one environment to another, and an inventory scanner which modifies inventories for each environment based on monitored asset movements. The present invention is of especial benefit to autonomic and on-demand computing architectures. | 04-16-2009 |
20110214009 | Creation of Highly Available Pseudo-Clone Standby Servers for Rapid Failover Provisioning - Near clones for a set of targeted computing systems are provided by determining a highest common denominator set of components among the computing systems, producing a pseudo-clone configuration definition, and realizing one or more pseudo-clone computing systems as partially configured backups for the targeted computing systems. Upon a planned failover, actual failure, or quarantine action on a targeted computing system, a difference configuration is determined to complete the provisioning of the pseudo-clone system to serve as a replacement system for the failed or quarantined system. Failure predictions can be used to implement the pseudo-clone just prior to an expected first failure of any of the targeted systems. The system can also interface to an on-demand provisioning management system to effect automated workflows to realize pseudo-clones and replacement systems automatically, as needed. | 09-01-2011 |
20110214010 | Creation of Highly Available Pseudo-Clone Standby Servers for Rapid Failover Provisioning - Near clones for a set of targeted computing systems are provided by determining a highest common denominator set of components among the computing systems, producing a pseudo-clone configuration definition, and realizing one or more pseudo-clone computing systems as partially configured backups for the targeted computing systems. Upon a planned failover, actual failure, or quarantine action on a targeted computing system, a difference configuration is determined to complete the provisioning of the pseudo-clone system to serve as a replacement system for the failed or quarantined system. Failure predictions can be used to implement the pseudo-clone just prior to an expected first failure of any of the targeted systems. The system can also interface to an on-demand provisioning management system to effect automated workflows to realize pseudo-clones and replacement systems automatically, as needed. | 09-01-2011 |
20130024720 | Creation of Highly Available Pseudo-Clone Standby Servers for Rapid Failover Provisioning - Near clones for a set of targeted computing systems are provided by determining a highest common denominator set of components among the computing systems, producing a pseudo-clone configuration definition, and realizing one or more pseudo-clone computing systems as partially configured backups for the targeted computing systems. Upon a planned failover, actual failure, or quarantine action on a targeted computing system, a difference configuration is determined to complete the provisioning of the pseudo-clone system to serve as a replacement system for the failed or quarantined system. Failure predictions can be used to implement the pseudo-clone just prior to an expected first failure of any of the targeted systems. The system can also interface to an on-demand provisioning management system to effect automated workflows to realize pseudo-clones and replacement systems automatically, as needed. | 01-24-2013 |
Patent application number | Description | Published |
20090075284 | METABOLOMIC PROFILING OF PROSTATE CANCER - The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. | 03-19-2009 |
20090155826 | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same - Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. | 06-18-2009 |
20100279337 | Biomarkers Related To Metabolic Age and Methods Using The Same - Biomarkers relating to metabolic age are provided, as well as methods for using such biomarkers as biomarkers for determining metabolic age. In addition, methods for modulating the metabolic age of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for metabolic age. | 11-04-2010 |
20100292331 | Biomarkers for Prostate Cancer and Methods Using the Same - Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer. | 11-18-2010 |
20110300571 | Determination of the Liver Toxicity of an Agent - The present invention provides various biomarkers for hepatotoxicity and various methods of using the biomarkers Some of the biomarkers within the scope of this invention are cholate, glycochenodeoxycholate, glycocholate, taurine, 3-hyroxy-2-ethylpropionate, 4-imidazoleacetate, tyramine, anthranilate, 2′-deoxycytidine, N-acetyl aspartate (NAA), beta-hydroxy-hexanoate, and sarcosine (N-methylglycine) The methods of using the biomarkers include exposing a first hepatocyte culture to a test agent and comparing the levels of the one or more biomarkers obtained in the first hepatocyte culture to the levels of the one or more biomarkers obtained in a second hepatocyte culture without the test agent, where differential levels of the one or more biomarkers in the first hepatocyte culture as compared to the levels in the second hepatocyte culture is indicative of the test agent being a hepatotoxicant. | 12-08-2011 |
20120122981 | Biomarkers Related to Insulin Resistance and Methods using the Same - Biomarkers relating to glucose disposal rate, insulin resistance, and/or insulin resistance-related disorders are provided. Methods based on the same biomarkers are also provided. | 05-17-2012 |
20120208215 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same - Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. | 08-16-2012 |
20130309697 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME - Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer. | 11-21-2013 |
20130338031 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same - Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. | 12-19-2013 |
20140051601 | METABOLOMIC PROFILING OF CANCER - The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. | 02-20-2014 |
20140303228 | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same - The disclosure provides biomarkers of amyotrophic lateral sclerosis (ALS). The disclosure also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS. | 10-09-2014 |
20140343865 | Biomarkers for Kidney Cancer and Methods Using the Same - Methods for identifying and evaluating biochemical entities useful as biomarkers for kidney cancer, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for kidney cancer. | 11-20-2014 |
20150065460 | Biomarkers Related to Insulin Resistance and Methods Using the Same - Biomarkers relating to pancreatic Beta-cell function, pancreatic Beta-cell glucose sensitivity, insulin resistance, and/or pancreatic Beta-cell-related disorders are provided. Methods based on the same biomarkers are also provided. | 03-05-2015 |
Patent application number | Description | Published |
20120022917 | SYSTEM AND METHOD FOR EVALUATING A CLIENT BASE - The present disclosure describes novel systems and methods that can be utilized to evaluate and/or direct an interaction with a consumer database and/or evaluate a consumer database, where the consumer database contains information about consumers and particular products and/or services held or used by the consumers. The interactions may be, for example, determining a strategy for sales, marketing, cross-selling, and/or retaining one or more of the consumers. The evaluations may include, for example, hierarchically ranking the consumers and/or determining a clustering of the consumers. | 01-26-2012 |
20130060607 | System and Method for Strategizing Interactions With a Client Base - The present disclosure describes novel systems and methods that can be utilized to evaluate and/or direct an interaction with a consumer database and/or evaluate a consumer database, where the consumer database contains information about consumers and particular products and/or services held or used by the consumers. The interactions may be, for example, determining a strategy for sales, marketing, cross-selling, and/or retaining one or more of the consumers. The evaluations may include, for example, hierarchically ranking the consumers and/or determining a clustering of the consumers. | 03-07-2013 |
20130096984 | SYSTEM AND METHOD FOR ESTIMATING RESIDUAL LIFETIME VALUE OF A CUSTOMER BASE UTILIZING SURVIVAL ANALYSIS - The present disclosure describes novel systems and methods that can be utilized to evaluate and/or direct an interaction with a consumer database and/or evaluate a consumer database, where the consumer database contains information about consumers and particular products and/or services held or used by the consumers. The interactions may be, for example, determining a strategy for sales, marketing, cross-selling, and/or retaining one or more of the consumers. The evaluations may include, for example, hierarchically ranking the consumers and/or determining a clustering of the consumers. | 04-18-2013 |
20130253983 | SYSTEM AND METHOD FOR ESTIMATING RESIDUAL LIFETIME VALUE OF A CUSTOMER BASE UTILIZING SURVIVAL ANALYSIS - The present disclosure describes novel systems and methods that can be utilized to evaluate and/or direct an interaction with a consumer database and/or evaluate a consumer database, where the consumer database contains information about consumers and particular products and/or services held or used by the consumers. The interactions may be, for example, determining a strategy for sales, marketing, cross-selling, and/or retaining one or more of the consumers. The evaluations may include, for example, hierarchically ranking the consumers and/or determining a clustering of the consumers. | 09-26-2013 |
20130253984 | SYSTEM AND METHOD FOR EVALUATING BANKING CONSUMERS AS A FUNCTION OF AGGREGATED RESIDUAL LIFETIME VALUES AND POTENTIAL LIFETIME VALUES - The present disclosure describes novel systems and methods that can be utilized to evaluate and/or direct an interaction with a consumer database and/or evaluate a consumer database, where the consumer database contains information about consumers and particular products and/or services held or used by the consumers. The interactions may be, for example, determining a strategy for sales, marketing, cross-selling, and/or retaining one or more of the consumers. The evaluations may include, for example, hierarchically ranking the consumers and/or determining a clustering of the consumers. | 09-26-2013 |
20130282439 | System and Method for Strategizing Interactions with a Client Base - The present disclosure describes novel systems and methods that can be utilized to evaluate and/or direct an interaction with a consumer database and/or evaluate a consumer database, where the consumer database contains information about consumers and particular products and/or services held or used by the consumers. The interactions may be, for example, determining a strategy for sales, marketing, cross-selling, and/or retaining one or more of the consumers. The evaluations may include, for example, hierarchically ranking the consumers and/or determining a clustering of the consumers. | 10-24-2013 |